BY080835 Inhibitors
BY080835, a protein of significant interest in cellular signaling, plays a pivotal role in various intracellular pathways, contributing to the regulation of essential cellular functions. As a multifunctional protein, BY080835 is primarily involved in modulating cell proliferation, survival, and differentiation, making it a critical player in maintaining cellular homeostasis.
At its core, BY080835 functions as a signaling hub, integrating inputs from diverse pathways such as RAS/MAPK, AKT/mTOR, JAK/STAT, NF-κB, Wnt/β-catenin, PI3K, Hedgehog, Notch, TLR/NF-κB, Hippo/YAP, and Sonic Hedgehog. Through intricate crosstalk, BY080835 orchestrates cellular responses, ensuring appropriate reactions to environmental cues and maintaining cellular equilibrium. The general mechanisms by which BY080835 inhibitors exert their effects vary, reflecting the diverse pathways involved. Sorafenib, for example, disrupts the RAS/MAPK pathway, suppressing the expression of SPRY4, a negative feedback regulator of BY080835. Rapamycin modulates the AKT/mTOR pathway, altering downstream processes that facilitate BY080835 activation. Each inhibitor strategically targets specific cellular pathways, leading to indirect inhibition of BY080835 and offering valuable insights for further research in cancer biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits BY080835 by disrupting the downstream RAS/MAPK pathway. Suppresses SPRY4 expression, a negative feedback regulator, leading to increased activity of BY080835. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Targets BY080835 indirectly by inhibiting the AKT/mTOR pathway. Reduces phosphorylation of key proteins downstream, altering cellular processes that facilitate BY080835 activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Disrupts the NF-κB pathway, influencing BY080835 indirectly. Downregulates expression of anti-apoptotic proteins, leading to increased vulnerability of cells to BY080835 inhibition. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Targets BY080835 by modulating the Wnt/β-catenin pathway. Downregulates Wnt ligands, altering the signaling cascade and attenuating BY080835 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
BY080835 inhibition through interference with the PI3K pathway. Modulates downstream effectors like FOXO, impacting cellular processes that contribute to BY080835 activation. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $63.00 $128.00 $200.00 | 6 | |
Indirect inhibition of BY080835 by affecting the Hedgehog pathway. Alters expression of GLI transcription factors, leading to downstream changes that suppress BY080835 activity. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
Inhibits BY080835 by targeting the Notch signaling pathway. Modulates expression of key components, disrupting the pathway and indirectly attenuating BY080835 activation. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $122.00 $516.00 | 55 | |
BY080835 inhibition through interference with the TLR/NF-κB pathway. Modulates inflammatory signaling, impacting the feedback loop that regulates BY080835 activity. | ||||||
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $347.00 $2710.00 | 5 | |
Targets BY080835 by influencing the Hippo/YAP pathway. Modulates YAP activity, altering downstream signaling events that contribute to BY080835 activation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Indirect inhibition of BY080835 through modulation of the mTOR pathway. Alters mTORC1 activity, affecting cellular processes that contribute to BY080835 activation. | ||||||